{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:19:18Z","timestamp":1785417558918,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,24]],"date-time":"2013-11-24T00:00:00Z","timestamp":1385251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12032-013-0777-3","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T05:47:03Z","timestamp":1385185623000},"source":"Crossref","is-referenced-by-count":38,"title":["Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models"],"prefix":"10.1007","volume":"31","author":[{"given":"Leilei","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,24]]},"reference":[{"issue":"1","key":"777_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330. doi: 10.3322\/caac.21166 .","journal-title":"CA Cancer J Clin"},{"key":"777_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7150\/jca.2.363","volume":"2","author":"D Sangiolo","year":"2011","unstructured":"Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363\u20138.","journal-title":"J Cancer"},{"issue":"12","key":"777_CR3","first-page":"954","volume":"14","author":"H Luo","year":"2011","unstructured":"Luo H, Zhou X. Researche advances on CIK cells and their clinical use in lung cancer. Chin J Lung Cancer. 2011;14(12):954\u20139. doi: 10.3779\/j.issn.1009-3419.2011.12.10 .","journal-title":"Chin J Lung Cancer"},{"key":"777_CR4","doi-asserted-by":"crossref","first-page":"439053","DOI":"10.1155\/2011\/439053","volume":"2011","author":"O Draghiciu","year":"2011","unstructured":"Draghiciu O, Nijman HW, Daemen T. From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol. 2011;2011:439053. doi: 10.1155\/2011\/439053 .","journal-title":"Clin Dev Immunol"},{"issue":"43","key":"777_CR5","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109(43):17561\u20136. doi: 10.1073\/pnas.1215397109 .","journal-title":"Proc Natl Acad Sci USA"},{"key":"777_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2012.00021","volume":"3","author":"S Chouaib","year":"2012","unstructured":"Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21. doi: 10.3389\/fimmu.2012.00021 .","journal-title":"Front Immunol"},{"issue":"8","key":"777_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00432-010-0770-6","volume":"136","author":"G Huang","year":"2010","unstructured":"Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136(8):1201\u201311. doi: 10.1007\/s00432-010-0770-6 .","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"777_CR8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jpedsurg.2010.02.068","volume":"45","author":"AL Myers","year":"2010","unstructured":"Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg. 2010;45(6):1080\u20135. doi: 10.1016\/j.jpedsurg.2010.02.068 .","journal-title":"J Pediatr Surg"},{"issue":"12","key":"777_CR9","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/1078-0432.CCR-11-3000","volume":"18","author":"RS Turley","year":"2012","unstructured":"Turley RS, Fontanella AN, Padussis JC, Toshimitsu H, Tokuhisa Y, Cho EH, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012;18(12):3328\u201339. doi: 10.1158\/1078-0432.CCR-11-3000 .","journal-title":"Clin Cancer Res"},{"issue":"1","key":"777_CR10","first-page":"70","volume":"1","author":"J Jz","year":"1980","unstructured":"Jz J. The additive of drug combination. Acta Pharm Sinica. 1980;1(1):70\u20133.","journal-title":"Acta Pharm Sinica"},{"issue":"6","key":"777_CR11","doi-asserted-by":"crossref","first-page":"e65757","DOI":"10.1371\/journal.pone.0065757","volume":"8","author":"S Shi","year":"2013","unstructured":"Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE. 2013;8(6):e65757. doi: 10.1371\/journal.pone.0065757 .","journal-title":"PLoS ONE"},{"issue":"7","key":"777_CR12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/14653249.2012.694419","volume":"14","author":"YC Linn","year":"2012","unstructured":"Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, et al. A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012;14(7):851\u20139. doi: 10.3109\/14653249.2012.694419 .","journal-title":"Cytotherapy"},{"issue":"6","key":"777_CR13","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","volume":"18","author":"L Liu","year":"2012","unstructured":"Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 2012;18(6):1751\u20139. doi: 10.1158\/1078-0432.CCR-11-2442 .","journal-title":"Clin Cancer Res"},{"issue":"25","key":"777_CR14","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3748\/wjg.v17.i25.3002","volume":"17","author":"X Huang","year":"2011","unstructured":"Huang X, Chen YT, Song HZ, Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol. 2011;17(25):3002\u201311. doi: 10.3748\/wjg.v17.i25.3002 .","journal-title":"World J Gastroenterol"},{"issue":"20","key":"777_CR15","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1158\/0008-5472.CAN-12-1952","volume":"72","author":"P Berraondo","year":"2012","unstructured":"Berraondo P, Umansky V, Melero I. Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res. 2012;72(20):5159\u201364. doi: 10.1158\/0008-5472.CAN-12-1952 .","journal-title":"Cancer Res"},{"issue":"3","key":"777_CR16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ijc.25702","volume":"129","author":"X Huang","year":"2011","unstructured":"Huang X, Huang G, Song H, Chen L. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int J Cancer. 2011;129(3):648\u201358. doi: 10.1002\/ijc.25702 .","journal-title":"Int J Cancer"},{"issue":"4","key":"777_CR17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/path.4053","volume":"227","author":"M Singh","year":"2012","unstructured":"Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. 2012;227(4):417\u201330. doi: 10.1002\/path.4053 .","journal-title":"J Pathol"},{"issue":"3","key":"777_CR18","doi-asserted-by":"crossref","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486. doi: 10.1101\/cshperspect.a006486 .","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2\u20133","key":"777_CR19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mvr.2007.05.003","volume":"74","author":"D Fukumura","year":"2007","unstructured":"Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2\u20133):72\u201384. doi: 10.1016\/j.mvr.2007.05.003 .","journal-title":"Microvasc Res"},{"issue":"3","key":"777_CR20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2012.07.013","volume":"164","author":"S Taurin","year":"2012","unstructured":"Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link? J Control Release. 2012;164(3):265\u201375. doi: 10.1016\/j.jconrel.2012.07.013 .","journal-title":"J Control Release"},{"key":"777_CR21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-60327-345-9_12","volume":"611","author":"RJ Young","year":"2010","unstructured":"Young RJ, Moller A. Immunohistochemical detection of tumour hypoxia. Methods Mol Biol. 2010;611:151\u20139. doi: 10.1007\/978-1-60327-345-9_12 .","journal-title":"Methods Mol Biol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0777-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-013-0777-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0777-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:27Z","timestamp":1559442147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-013-0777-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,24]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s12032-013-0777-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,24]]},"article-number":"777"}}